AMPH
Amphastar Pharmaceuticals, Inc.

Market cap $846.87M
Enterprise value $842.43M
Employees 1,541
Revenue $243M
EBITDA $8.94M
Income $298k
EPS 0.00
P/E 245.32
Forward P/E 29.71
EV/EBITDA 94.28
PEG 3.00
Earnings date 2017-05-11
Volume 97.4k / 208k
Relative vol. 0.47 ×
Sales Q/Q -8.86%
Sales Y/Y 10.48%
Est. EPS Q/Q -300.00%
Beta 1.35
Mean Recomm. 2.00
IPO year 2014
Country United States
RSI 45.06
Range $18.40 – $19.29
52 weeks $12.05 – $19.95
SMA 50 $19 -2.59%
SMA 200 $18 -6.83%
1 year target $22 +16.97%

Intraday

5 days

1 month

3 months

6 months

1 year

5 years

10 years

All time

Date
#
Company
Insider Title
Trans.
Transaction
Shares Price per share Total price Shares after Source
2017-12-14 Stephen B. Shohet
Director
Director Option exercise 7,866 $10.77 $84,717
2017-12-14
31,982
2017-12-12 Diane G. Gerst
EVP, QA & Regulatory Affairs
EVP, QA & Regulatory Affairs Sale 523 $18.96 $9,916
2017-12-12
30,687
2017-12-07 Stephen B. Shohet
Director
Director Option exercise 7,862 $10.77 $84,674
2017-12-07
31,978
2017-12-01 William J Peters
CFO, SVP & Treasurer
CFO, SVP & Treasurer Sale 6,226 $19.67 $122,465
2017-12-01
78,314
2017-11-30 Stephen B. Shohet
Director
Director Option exercise 7,862 $10.77 $84,674
2017-11-30
31,978
2017-11-28 Diane G. Gerst
EVP, QA & Regulatory Affairs
EVP, QA & Regulatory Affairs Sale 523 $18.15 $9,492
2017-11-28
31,210
2017-11-22 Stephen B. Shohet
Director
Director Option exercise 7,862 $10.77 $84,674
2017-11-22
31,978
2017-11-21 Diane G. Gerst
EVP, QA & Regulatory Affairs
EVP, QA & Regulatory Affairs Sale 523 $18.81 $9,838
2017-11-21
31,733
2017-11-16 Stephen B. Shohet
Director
Director Option exercise 7,862 $10.77 $84,674
2017-11-16
31,978
2017-11-15 Diane G. Gerst
EVP, QA & Regulatory Affairs
EVP, QA & Regulatory Affairs Sale 523 $17.77 $9,294
2017-11-15
32,256
2017-11-13 Jack Y.Luo Mary Z. Zhang
CEO & Chief Science OfficerCOO Chief Scientist & Chairman
CEO & Chief Science OfficerCOO Chief Scientist & Chairman Option exercise 506,337 $12.02 $6,086,171
2017-11-13
1,263,378
2017-11-09 Stephen B. Shohet
Director
Director Option exercise 7,862 $10.77 $84,674
2017-11-09
31,978
2017-11-07 Diane G. Gerst
EVP, QA & Regulatory Affairs
EVP, QA & Regulatory Affairs Sale 523 $17.93 $9,377
2017-11-07
32,779
2017-11-02 Stephen B. Shohet
Director
Director Option exercise 7,862 $10.77 $84,674
2017-11-02
31,978
2017-10-26 Stephen B. Shohet
Director
Director Option exercise 7,862 $10.77 $84,674
2017-10-26
31,978
2017-10-24 Diane G. Gerst
EVP, QA & Regulatory Affairs
EVP, QA & Regulatory Affairs Sale 523 $18.29 $9,566
2017-10-24
33,302
2017-10-19 Stephen B. Shohet
Director
Director Option exercise 7,862 $10.77 $84,674
2017-10-19
31,978
2017-10-17 Diane G. Gerst
EVP, QA & Regulatory Affairs
EVP, QA & Regulatory Affairs Sale 523 $18.48 $9,665
2017-10-17
33,825
2017-10-13 William J Peters
CFO, SVP & Treasurer
CFO, SVP & Treasurer Sale 3,026 $18.56 $56,163
2017-10-13
83,496
2017-10-12 Stephen B. Shohet
Director
Director Option exercise 7,862 $10.77 $84,674
2017-10-12
31,978
2017-10-05 Diane G. Gerst
EVP, QA & Regulatory Affairs
EVP, QA & Regulatory Affairs Option exercise 8,444 $11.33 $95,671
2017-10-05
42,792
2017-10-04 Floyd F. Petersen
Director
Director Option exercise 39,312 $10.77 $423,390
2017-10-04
103,873
2017-10-02 Michael A Zasloff
Director
Director Option exercise 63,624 $10.77 $685,230
2017-10-02
101,879
2017-09-13 Jack Y.Luo Mary Z. Zhang
CEO & Chief Science OfficerCOO Chief Scientist & Chairman
CEO & Chief Science OfficerCOO Chief Scientist & Chairman Option exercise 315,619 $11.53 $3,639,087
2017-09-13
1,197,337
2017-08-14 Richard K Prins
Director
Director Option exercise 10,000 $10.77 $107,700
2017-08-14
33,844
2017-06-08 Richard K Prins
Director
Director Option exercise 10,000 $10.77 $107,700
2017-06-08
38,844
2017-06-01 Michael A Zasloff
Director
Director Option exercise 15,000 $10.77 $161,550
2017-06-01
47,411

Notable SEC filings of Amphastar Pharmaceuticals, Inc.

Date Contents
Source
2017-08-09 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2017-07-24 8-K Other Events; Financial Statements and Exhibits
2017-06-09 8-K Submission of Matters to a Vote of Security Holders
2017-05-10 10-Q Quarterly report
2017-05-08 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2017-03-15 10-K Yearly report
2017-03-13 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2016-12-27 8-K Other Events; Financial Statements and Exhibits
2016-11-10 8-K Entry into a Material Definitive Agreement; Other Events
2016-11-09 10-Q Quarterly report
2016-11-08 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2016-08-09 10-Q Quarterly report
2016-08-08 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2016-08-04 8-K Other Events; Financial Statements and Exhibits
2016-07-07 8-K Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibits
2016-06-10 8-K Submission of Matters to a Vote of Security Holders
2016-05-10 10-Q Quarterly report
2016-05-09 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2016-03-15 10-K Yearly report
2016-03-14 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2015-11-13 10-Q Quarterly report
2015-11-12 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2015-08-13 10-Q Quarterly report
2015-08-12 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2015-06-22 8-K Other Events; Financial Statements and Exhibits
2015-06-01 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits
Market Perform BMO Capital 9 November 2017
Outperform → Market Perform
Raymond James 8 November 2017

Amphastar Pharmaceuticals executives

Insider Title Age Since Compensation
Jack Zhang (70)
Chief Executive Officer, Chief Scientific Officer, Director since 2013
Chief Executive Officer, Chief Scientific Officer, Director 70 2013 $5,733,880
Mary Luo (67)
Chief Operating Officer, Chief Scientist and Chairman of the Board since 2005
Chief Operating Officer, Chief Scientist and Chairman of the Board 67 2005 $3,006,140
Jason Shandell (43)
President, General Counsel, Director since 2017
President, General Counsel, Director 43 2017 $2,661,670
Michael Zasloff (71)
Lead Independent Director since 2016
Lead Independent Director 71 2016 $281,877
Richard Koo (76)
Independent Director since 2002
Independent Director 76 2002 $280,002
Howard Lee (54)
Independent Director since 2007
Independent Director 54 2007 $277,627
Stephen Shohet (82)
Independent Director since 2010
Independent Director 82 2010 $275,002
Richard Prins (60)
Independent Director since 2002
Independent Director 60 2002 $273,002
Floyd Petersen (73)
Independent Director since 2004
Independent Director 73 2004 $268,002
Rong Zhou (58)
Executive Vice President - Production Center and President of Armstrong Pharmaceuticals, Inc. since 2015
Executive Vice President - Production Center and President of Armstrong Pharmaceuticals, Inc. 58 2015
Diane Gerst (57)
Executive Vice President - Quality Assurance and Regulatory Affairs and President of Amphastar Nanjing Pharmaceuticals Inc since 2015
Executive Vice President - Quality Assurance and Regulatory Affairs and President of Amphastar Nanjing Pharmaceuticals Inc 57 2015
William Peters (49)
Chief Financial Officer, Senior Vice President, Treasurer and President of Armstrong Pharmaceuticals, Inc. since 2016
Chief Financial Officer, Senior Vice President, Treasurer and President of Armstrong Pharmaceuticals, Inc. 49 2016
Amphastar Pharmaceuticals, Inc. logo

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. It operates in two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company's product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, which include critical care drugs, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; and procainamide for documented ventricular arrhythmias. In addition, the company manufactures and distributes recombinant human insulin and porcine insulin. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate that is intended to be used for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. The company was established in 1996 and is headquartered in Rancho Cucamonga, California.

  • Amphastar Pharmaceuticals, Inc., 11570 6th Street, Rancho Cucamonga 91730, United States
  • amphastar.com
  • 909-980-9484

Quarterly EPS estimates

Profit margin

Debt to assets

Cash flow

Balance sheet

(in millions) 2017Q3 2017Q2 2017Q1 2016Q4
Current assets
Cash $71.075 $86.699 $78.285 $73.744
Short term investments $2.522 $0.727 $0.746 $0.527
Net receivables $24.595 $24.509 $26.102 $26.799
Inventory $69.64 $74.457 $78.137 $79.754
Other current assets $8.66 $7.187 $8.147 $3.272
Total current assets $176.492 $193.579 $191.417 $184.096
Long term investments
Property, plant & equipment $173.046 $161.72 $157.389 $152.944
Goodwill
Intangible assets $45.731 $45.869 $45.993 $50.307
Other assets $10.623 $10.955 $8.939 $9.39
Deferred long term asset charges $31.874 $31.874 $31.874 $31.001
Total assets $437.766 $443.997 $435.612 $427.738
Current liabilities
Accounts payable $47.536 $54.541 $65.531 $53.451
Short long term debt $6.212 $6.205 $5.263 $5.366
Other current liabilities $3.649 $2.955 $2.067 $1.8
Total current liabilities $57.397 $63.701 $72.861 $60.617
Long term debt $42.232 $40.107 $31.148 $32.356
Other liabilities $4.681 $4.914 $4.289 $3.958
Deferred long term liabilities $2.801 $1.961 $1.753 $1.552
Minority interest
Total liabilities $107.111 $110.683 $110.051 $98.483
Stockholders' equity
Stock option warrants
Common stock $0.005 $0.005 $0.005 $0.005
Retained earnings $74.767 $74.592 $72.62 $70.855
Treasury stock -$44.73 -$37.168 -$28.19 -$20.032
Capital surplus $303.208 $299.105 $285.356 $283.123
Other stockholder equity -$2.595 -$3.22 -$4.23 -$4.696
Total stockholder equity $330.655 $333.314 $325.561 $329.255
Net tangible assets $284.924 $287.445 $279.568 $278.948
(in millions) 2016 2015 2014
Current assets
Cash $73.744 $67.359 $69.323
Short term investments $0.527
Net receivables $26.799 $33.471 $42.658
Inventory $79.754 $70.665 $82.332
Other current assets $3.272 $4.439 $3.683
Total current assets $184.096 $175.934 $197.996
Long term investments
Property, plant & equipment $152.944 $142.161 $138.289
Goodwill
Intangible assets $50.307 $39.901 $42.565
Other assets $9.39 $4.696 $3.588
Deferred long term asset charges $31.001 $27.444 $6.932
Total assets $427.738 $390.136 $389.37
Current liabilities
Accounts payable $53.451 $46.52 $39.07
Short long term debt $5.366 $10.934 $7.594
Other current liabilities $1.8 $2.501 $15.931
Total current liabilities $60.617 $59.955 $62.595
Long term debt $32.356 $30.165 $36.106
Other liabilities $3.958 $3.167 $0.989
Deferred long term liabilities $1.552 $1.339 $7.82
Minority interest
Total liabilities $98.483 $94.626 $107.51
Stockholders' equity
Stock option warrants
Common stock $0.005 $0.005 $0.004
Retained earnings $70.855 $60.323 $63.11
Treasury stock -$20.032 -$10.172 -$0.345
Capital surplus $283.123 $247.829 $220.745
Other stockholder equity -$4.696 -$2.475 -$1.654
Total stockholder equity $329.255 $295.51 $281.86
Net tangible assets $278.948 $255.609 $239.295

Income statement

(in millions) 2017Q3 2017Q2 2017Q1 2016Q4
Revenue
Total revenue $57.916 $65.187 $56.67 $63.543
Cost of revenue $37.275 $38.44 $33.842 $43.582
Gross profit $20.641 $26.747 $22.828 $19.961
Operating expenses
Research & development $10.04 $10.732 $11.25 $12.277
Selling, general & administrative $13.421 $13.83 $12.817 $12.194
Non-recurring
Other operating expenses
Total operating expenses
Operating income -$2.82 $2.185 $1.404 -$4.51
Income from continuing operations
Net other income $1.093 $1.225 $2.934 -$0.059
EBIT -$1.727 $3.41 $1.695 -$4.569
Interest expense $0.264 $0.237 $0.191 $0.054
Income before tax -$1.991 $3.173 $1.504 -$4.623
Income tax expense -$2.166 $1.201 $0.611 -$1.881
Minority interest
Net income from continuing ops $0.175 $1.972 $0.893 -$2.742
Non-recurring events
Discontinued operations
Extraordinary items
Effect of accounting change
Other items
Net income
EBITDA $0.175 $1.972 $0.893 -$2.742
Income (for common shares) $0.175 $1.972 $0.893 -$2.742
(in millions) 2016 2015 2014
Revenue
Total revenue $255.165 $251.519 $210.461
Cost of revenue $150.976 $174.172 $159.205
Gross profit $104.189 $77.347 $51.256
Operating expenses
Research & development $41.199 $37.271 $28.866
Selling, general & administrative $47.298 $46.974 $40.373
Non-recurring
Other operating expenses
Total operating expenses
Operating income $15.692 -$6.898 -$17.983
Income from continuing operations
Net other income $0.278 -$2.479 $0.444
EBIT $15.97 -$9.377 -$17.539
Interest expense $1.024 $0.987 $0.609
Income before tax $14.946 -$10.364 -$18.148
Income tax expense $4.414 -$7.577 -$7.449
Minority interest
Net income from continuing ops $10.532 -$2.787 -$10.699
Non-recurring events
Discontinued operations
Extraordinary items
Effect of accounting change
Other items
Net income
EBITDA $10.532 -$2.787 -$10.699
Income (for common shares) $10.532 -$2.787 -$10.699

Cash flow

(in millions) 2017Q3 2017Q2 2017Q1 2016Q4
Net income $0.175 $1.972 $0.893 -$2.742
Operating activities
Depreciation $3.838 $3.847 $3.83 $3.876
Net income adjustments $4.434 $4.38 $1.808 $0.497
Change in accounts receivable $0.089 $1.9 $0.92 -$0.379
Changes in liabilities -$6.341 -$7.997 $12.318 $1.922
Changes in inventory $5.417 $5.074 $1.891 $9.762
Changes in other operating activities -$5.14 -$4.602 $0.738 $1.07
Total cash flow from operations $2.472 $4.574 $22.398 $14.006
Investing activities
Capital expenditures -$11.413 -$6.301 -$7.267 -$5.337
Investments -$1.795 $0.019 -$0.219 $0.329
Other cash flows from investing $0.238 -$3.28 $1.392 -$2.105
Total cash flows from investing -$12.97 -$9.562 -$6.094 -$7.113
Financing activities
Dividends paid
Sale and purchase of stock -$7.615 $0.473 -$10.376 $2.56
Net borrowings $2.102 $9.842 -$1.342 -$4.684
Other cash flows from financing
Total cash flows from financing -$5.513 $10.315 -$11.718 -$1.261
Effect of exchange rate $0.387 $0.451 -$0.174 $0.124
Change in cash and equivalents -$15.624 $5.778 $4.412 $5.756
(in millions) 2016 2015 2014
Net income $10.532 -$2.787 -$10.699
Operating activities
Depreciation $14.636 $13.362 $14.611
Net income adjustments $13.095 $5.244 $1.521
Change in accounts receivable $6.377 -$11.012 $1.21
Changes in liabilities -$0.823 -$3.131 $5.5
Changes in inventory -$9.715 $9.775 $6.565
Changes in other operating activities $4.458 -$0.77 $2.344
Total cash flow from operations $38.56 $10.681 $21.052
Investing activities
Capital expenditures -$21.382 -$16.047 -$20.499
Investments -$0.527 -$0.527 -$0.527
Other cash flows from investing -$17.592 -$0.878 -$19.274
Total cash flows from investing -$39.501 -$16.925 -$39.773
Financing activities
Dividends paid
Sale and purchase of stock $10.731 $4.336 $35.935
Net borrowings -$4.454 -$2.206 -$2.709
Other cash flows from financing
Total cash flows from financing $7.14 $2.237 $32.117
Effect of exchange rate $0.081 $2.253 $0.845
Change in cash and equivalents $6.28 -$1.754 $14.241
Messenger